Common use of Responsibility to Develop Clause in Contracts

Responsibility to Develop. Sankyo is to be responsible for all clinical development and regulatory approvals and shall own all such approvals; provided that in the event that MTI terminates this Agreement pursuant to Section 14.2 hereof, Sankyo shall transfer all such registrations to MTI. MTI may attend meetings held by Sankyo respecting development of Licensed Compounds, and Sankyo will provide notice to MTI of such meetings in a reasonable and timely manner and solicit MTI input, but no such development meetings need be delayed, postponed or altered to accommodate participation by MTI. Notwithstanding the foregoing, *** Confidential Treatment Requested. Sankyo shall neither commence human clinical trials of any Compound, nor file any regulatory application therefor, unless and until such Compound is a Licensed Compound.